NONOF - Drugmakers comply with Medicare pricing talks despite lawsuits
2023-10-02 14:55:14 ET
More on Bristol-Myers, Merck, etc.
- Bristol-Myers: Out Of Favor (Rating Upgrade)
- Bristol-Myers Squibb: How Cheap Is Cheap Enough?
- Bristol-Myers Squibb Looks Grossly Overvalued With LOE Taking A Bite Out Of Topline
- Merck, Bristol Myers, AstraZeneca agree to Medicare drug pricing talks
- Merck wins FDA priority review for lung disease therapy
For further details see:
Drugmakers comply with Medicare pricing talks despite lawsuits